Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com Investing.com South Africa
Covered in this story
What has happened since
- Advanced Micro Devices is up 0.4% since this was published, 66 days ago.
- Ocular Therapeutix Inc is down 37.9% since this was published, 66 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Advanced Micro Devices
- Bank of America: $606 → $720 by Oct 2027 · Buy via FXLeaders
- UBS: $608 → $700 by Oct 2027 · Buy via Stocktwits
- Rosenblatt Securities: $608 → $665 by Oct 2027 · Buy via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Advanced Micro Devices →Dalsna Finance is currently tracking 55 stories mentioning Advanced Micro Devices, the earliest published 4 Aug 2026.
Summary aggregated from Investing.com South Africa's public RSS feed. The full reporting belongs to Investing.com South Africa — please read it on their site.